BIOBio-Rad Laboratories Inc.

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

Norman D. Schwartz

Location

California, USA

Exchange

NYSE

Website

https://bio-rad.com

Summary

Bio-Rad Laboratories, Inc.

Company Info

CEO

Norman D. Schwartz

Location

California, USA

Exchange

NYSE

Website

https://bio-rad.com

Summary

Bio-Rad Laboratories, Inc.

AI Insights for BIO
5 min read

Quick Summary

Bio-Rad Laboratories, Inc. is a U.S.-based manufacturer and distributor of life science research and clinical diagnostic products headquartered in Hercules, California. The company operates mainly through its Life Science and Clinical Diagnostics segments. Its Life Science business sells reagents, instruments, laboratory apparatus, and analytical systems used by academic researchers, biopharmaceutical companies, and industrial labs. Its Clinical Diagnostics business sells test systems, informatics tools, test kits, blood typing products, and quality controls used by hospitals, reference laboratories, transfusion labs, and diagnostic testing providers. Bio-Rad serves customers that need reliable laboratory workflows, regulated diagnostic performance, and tools for biological analysis, disease testing, and quality assurance.

Strengths

•

Bio-Rad's primary strengths include a long operating history, specialized laboratory expertise, and established positions in life science research and clinical diagnostics.

•

The company has an installed base of instruments and recurring consumable demand, which can support customer retention and repeat sales.

•

Its Clinical Diagnostics segment benefits from regulated laboratory workflows where reliability, quality controls, and validated testing processes are highly valued.

•

The company's Sartorius stake provides a significant financial asset that can enhance intrinsic value and create strategic optionality.

•

Bio-Rad also has meaningful global reach, technical credibility, and product breadth across research reagents, laboratory instruments, informatics, blood typing, and diagnostic quality control.

Key Risks

•

Bio-Rad faces competitive risk from larger and better-capitalized companies such as Thermo Fisher, Danaher, Roche, Abbott, Siemens Healthineers, Agilent, and Beckman Coulter.

•

Demand risk exists if pharmaceutical companies reduce research spending, biotech funding remains constrained, or academic budgets weaken.

•

Clinical diagnostics products carry regulatory, quality, reimbursement, and product-liability risks because customers operate in highly regulated healthcare environments.

•

Currency fluctuations and international market conditions can affect reported revenue and profitability because Bio-Rad sells products globally.

What to Watch

The most notable company-specific event in the recent news was Bio-Rad's launch of the IH-500 automated blood typing and screening system for small and mid-size transfusion laboratories in Europe, Asia, Africa, Australia, and Latin America.
This launch strengthens the company's Clinical Diagnostics segment and targets customers that need improved automation, safety, and workflow consistency in immunohematology.
The product supports gel card testing, reduces manual handling through robotic automation, and integrates with Bio-Rad's data management software.
During the most recent reported quarter, the company generated 651 million dollars in revenue and 72.6 million dollars in operating income, while net income was much higher at 371.4 million dollars.
Recent commentary also emphasized the value of Bio-Rad's approximately 37 percent stake in Sartorius, which remains an important part of the investment case even though it does not directly appear in revenue or EBITDA.

Price Drivers

•

Bio-Rad's stock price is likely driven by earnings trends, revenue growth in Life Science and Clinical Diagnostics, margins, cash flow conversion, and investor expectations for laboratory demand.

•

The company reported Q3 2026 revenue of 651 million dollars, gross profit of 345.8 million dollars, operating income of 72.6 million dollars, and net income of 371.4 million dollars, which suggests reported earnings are materially influenced by items beyond normal operating income.

•

A major valuation factor is Bio-Rad's large stake in Sartorius, which can create hidden asset value and cause reported earnings to move with changes in that investment.

•

The stock's valuation metrics, including a price-to-earnings ratio of 46.2147 and price-to-book value of 1.4327, suggest investors may be looking beyond near-term operating earnings toward asset value, strategic optionality, or long-term growth.

•

Broader drivers include interest rates, healthcare capital spending, biopharma research funding, hospital purchasing cycles, currency movements, and sentiment toward life science tools companies.

Recent News

•

Recent news highlighted Bio-Rad's hidden asset value from its approximately 37 percent stake in Sartorius, which is described as being worth billions and as a major contributor to earnings even though it does not appear in revenue or EBITDA.

•

Analysts have suggested that after adjusting for this stake, Bio-Rad appears closer to fairly valued while still offering long-term upside.

•

Bio-Rad also launched the IH-500 automated blood typing and screening system for small and mid-size transfusion labs across Europe, Asia, Africa, Australia, and Latin America.

•

The system is intended to improve workflow, reduce manual labor, increase safety, and integrate with Bio-Rad data management software.

•

Other items in the supplied news feed involve unrelated companies with similar bio-related names, so they should not be treated as direct Bio-Rad corporate developments.

Market Trends

•

The broader market trends affecting Bio-Rad include healthcare digitization, laboratory automation, growth in clinical informatics, and the increasing need for efficient diagnostic workflows.

•

The microfluidics market is expected to grow meaningfully from 2026 to 2030, driven by lab-on-a-chip research, miniaturized diagnostics, pharmaceutical research, point-of-care testing, smart labs, and personalized medicine.

•

North America remains an important region for life science tools growth, while international diagnostics markets offer opportunities for products such as automated blood typing systems.

•

At the same time, life science tools companies are facing mixed end-market demand because biopharma funding, academic grants, and capital equipment purchasing can fluctuate.

•

Investors are also increasingly focused on margins, free cash flow, valuation discipline, and whether companies can convert technology trends into durable recurring revenue.

AI-generated summary for educational purposes only. Not investment advice. Always do your own research before investing.

Community Research

Research from investors like you

Be the first to share your analysis on BIO

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

avatar
@Ok_West_5560 9 months ago

Market recap: Stocks recover as CPI comes in cool, chips and crypto rally

Market recap: Stocks recover as CPI comes in cool, chips and crypto rally

post thumbnail

No more topics to show